Aldeyra Therapeutics Inc. CEO Todd Brady told BioWorld that the missed phase IIb primary endpoint with aldehyde trapper ADX-102 in allergic conjunctivitis (AC) was “retrofitted for another class of drugs [i.e., antihistamines], which is inactive after five to 10 minutes. We would have been viewed as having three eyes if we had picked something else as the main goal,” he said, adding that the outlook is likely “to change after the end-of-the phase II meeting” with the FDA.